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Abstract
Background: The characterization of HIV-1-specific T cell responses in people infected with
locally circulating HIV-1 strain will facilitate the development of HIV-1 vaccine. Sixty intravenous
drug users infected with HIV-1 circulating recombinant form 07_BC (CRF07_BC), which has been
spreading rapidly in western China from north to south, were recruited from Xinjiang, China to
assess the HIV-1-specific T cell responses at single peptide level with overlapping peptides (OLP)
covering the whole concensus clades B and C proteome.
Results:  The median of the total magnitude and total number of OLPs recognized by CTL
responses were 10925 SFC/million PBMC and 25 OLPs, respectively, when tested by clade C
peptides, which was significantly higher tha n  w h e n  t e s t e d  b y  c l a d e  B  p e p t i d e s .  T h e
immunodominant regions, which cover 14% (58/413) of the HIV-1 proteome, are widely
distributed throughout the HIV-1 proteome except in Tat, Vpu and Pol-PR, with Gag, Pol-RT, Pol-
Int and Nef being most frequently targeted. The subdominant epitopes are mostly located in p24,
Nef, integrase, Vpr and Vif. Of the responses directed to clade C OLPs, 61.75% (972/1574) can be
observed when tested with corresponding clade B OLPs. However, Pol-PR and Vpu tend to be
targeted in the clade B sequence rather than the clade C sequence, which is in line with the
recombinant pattern of CRF07_BC. Stronger and broader CTL responses in subjects with CD4 cell
counts ranging from 200 to 400/mm3 were observed when compared to those with less than 200/
mm3 or more than 400/mm3, though there have been no significant correlations identified between
the accumulative CTL responses or overall breadth and CD4 cell count or plasma viral load.
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Conclusion: This is the first study conducted to comprehensively address T cell responses in
Chinese subjects infected with HIV-1 CRF07_BC in which subtle differences in cross-reactivity
were observed, though similar patterns of overall immune responses were demonstrated with
clade B infected populations. The immunodominant regions identified in this population can
facilitate future HIV-1 vaccine development in China.
Background
HIV-1 specific cytotoxic T lymphocyte (CTL) responses
play pivotal roles in driving HIV-1 evolution [1-3] and
controlling viral infection [4,5]. Immune escape through
mutations within CTL epitopes is rapidly accumulated in
the HIV-1 genome [1-3], indicating the existence of a
strong selective pressure of immune responses on HIV-1
evolution. Dramatic declines of initial peak viremia to
viral set point are observed in acute HIV-1 infection with
the emergence of CTL responses[4] and strong CTL
responses are detected in long-term nonprogressors with
chronic HIV-1 infection [5]. At the population level, the
correlation between HIV-1-specific, especially Gag-spe-
cific, CTL responses and immune control have been
observed and confirmed in independent cohort studies
[6-8]. Therefore, prophylactic and therapeutic HIV-1-spe-
cific vaccine candidates aiming at eliciting potent HIV-1-
specific T cell responses are increasingly being tested in
pre-clinical and clinical trials.
The measurement of CTL responses using peptide sets
covering the whole HIV-1 expressed genome has been
employed in many previous studies and covering multiple
ethnicities including African, Caucasian, and Hispanic
populations [9-13]. From these studies, consistent CTL
targeting of immunodominant regions in the HIV-1 pro-
teome has been recorded [10] and a high degree of inter-
clade cross-reactivity of HIV-1-specific T cell responses at
the single peptide level has been observed [14]. However,
the high genetic diversity of HIV-1, which is driven by
high mutation rates and inter-subtype recombination
rates, is a major obstacle in the successful immune con-
tainment of viral infection and therefore the design of an
HIV-1 vaccine [15]. Previous studies have mainly focused
on populations infected with HIV-1 clades B and clade C,
which are found circulating widely throughout the world.
However, the characterization of CTL responses in people
infected with locally circulating HIV-1 has yet to be thor-
oughly conducted.
As a developing and most populous country, China is cur-
rently facing great challenges of the HIV-1 epidemic and
650,000 people are estimated to be living with HIV/AIDS
in China by the end of 2005[16]. The epidemic is mainly
driven by the wide spread of clade B' in former plasma
donors and B'/C recombinant (Circulating Recombinant
Form 07_BC, CRF07_BC) in intravenous drug users
(IDUs)[17]. The CRF07_BC, showing mosaic pattern in its
genome with a clade C backbone inserted by several clade
Thai B fragments in Gag, Pol, Env and accessory
genes[18,19] has been spreading rapidly in western China
from north to south [20-22]. In this study, we assessed the
profile of CTL responses in a Chinese IDU population
infected with HIV-1 CRF07_BC. By employing ELISPOT
using 2 sets of peptides covering the consensus clades B
and C HIV-1 whole expressed genome, we have evaluated
the breadth, magnitude, immunodominance and cross-
recognition of CTL responses in this CRF07_BC infected
Chinese population. The correlation between CTL
responses and the containment of viral replication was
also explored.
Results
Previous studies have shown that HIV-1 clade C infection
may result in decreased disease progression when com-
pared to clade B infection, which also correlates with the
rapid outspread of clade C strains in South Africa and the
Indian subcontinent [23-25]. To obtain new insight on
this issue, here we focused on the immunological
responses of a Chinese population infected with
CRF07_BC, a form of B'/C recombinant whose genome
comprises of a clade C backbone and several insertions
derived from Thai B[18,21,22].
ELISPOT measured the CD8 CTL responses
We compared the cumulative HIV-1 specific T cell
responses, which were derived from the addition of indi-
vidual positive responses in ELISPOT assays at the single
peptide level and in ICS assays using peptide pools. The
data indicate that the ELISPOT results are very consistent
with the ICS results (R = 0.96, p < 0.001). Three-color ICS
was used to discriminate between the CD8 and CD4 T cell
responses measured in ELISPOT and only 3 of the 60 sub-
jects had significant CD4 T cell responses in this study.
The magnitude and breadth of HIV-1 specific CTL 
responses
We examined the magnitude and frequency of recognition
at the single peptide level in this study population (Figure
1, Table 1). Similar clustering patterns of CTL responses
targeting the clades B and C proteome were observed (Fig-
ure 1A). However, when looking at the single peptide
level, the average magnitude of CTL responses and percent
of responders in the study population were significantlyRetrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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different between clades B and C peptide sets (p value of
0.009 and <0.001 respectively, Wilcoxon Signed Rank
Test) (Figure 1B, C).
In Table 1, we have summarized the total and protein-spe-
cific magnitude and breadth of CTL responses measured
in this study population for clades B and C peptides. Over-
all, we find that the responses targeting clade C proteins
are stronger and broader than clade B proteins, with the
exceptions being the Pol-PR and Vpu proteins. When
tested with clade B peptides, the median of the total mag-
nitude was 6,920 SFC/million PBMC with a range of 430–
66,290 SFC/million PBMC, which is significantly lower
than when tested by clade C peptides (median of 10925
SFC/million PBMC with the range of 210–66,130 SFC/
million PBMC) (p < 0.001, paired t-test). For the median
of the total number of OLPs recognized, there was also a
significant difference between clades B and C peptides
(median of 20.0 OLPs with the range of 4–59 OLPs by
clade B peptide versus 24.5 OLPs with the range of 3–63
OLPs by clade C peptide, p < 0.001, paired t-test). When
responses, within specific gene products, targeting clades
B and C peptides were compared, the responses targeting
Gag-p17, Env-gp120, Env-gp41, Pol-RT, Pol-RNase pro-
teins are significantly broader and stronger for clade C
(Table 1). For Rev, the difference in magnitude is of no
significance, while the breadth is statistically significant
(clade C > B). However, we observed that for Pol-PR and
Vpu proteins, the responses targeting clade B proteins are
broader and stronger than for clade C.
We have observed that up to 71.8% of the expressed HIV-
1 clade C proteome can be targeted in this study popula-
tion, compared with only 63.7% of the expressed HIV-1
clade B proteome. The most frequently targeted proteins
are Gag-p24, Nef and Pol-RT, to which more than 85% of
the subjects mounted CTL responses. However, only less
than 20% of subjects recognize at least one peptide within
the Vpu and Tat proteins.
Immunodominance and cross-recognition analysis
We tried to identify the immunodominant region in the
B'/C recombinant strains and found that there are 52 and
37 peptides from the clades C and B proteome, respec-
tively, targeted by at least 15% of the subjects (Figure 2).
These immunodominant OLPs (52 clade C and 37 clade
B, total 89) cover 14% (58/413) of the HIV-1 proteome.
In other words, 62 of the immunodominant OLPs
Table 1: Distribution of CTL Responses (breadth and strength) between HIV proteins
Protein No. of Peptides No. of OLP targeted at least 
once in the cohort (%)
No. of subjects with responses 
(%)
CTL strength (Mean ± SD) 
(SFC/106 PBMC)
BCBCBCBC
Gag-p17* 17 17 14(82.4%) 16(94.1%) 32(53.3%) 43(71.7%) 610 ± 1185 964 ± 1340
Gag-p24 31 31 30(96.8%) 30(96.8%) 51(85.0%) 52(86.7%) 3155 ± 3894 2935 ± 3390
Gag-p15 19 19 12(63.2%) 13(68.4%) 32(53.3%) 34(56.7%) 767 ± 1495 698 ± 1290
Gag 67 67 56(83.6%) 59(88.1%) 55(91.7%) 54(90.0%) 4532 ± 5512 4597 ± 5073
Pol – Pro*# 21 21 12(57.1%) 6(28.6%) 22(36.7%) 11(18.3%) 437 ± 949 240 ± 729
Pol – RT* 59 59 40(67.8%) 47(79.7%) 46(76.7%) 53(88.3%) 1047 ± 1461 2104 ± 2691
Pol – Rnase* 17 17 9(52.9%) 12(70.6%) 14(23.3%) 33(55.0%) 250 ± 1066 562 ± 1258
Pol – Int 36 36 27(75.0%) 30(83.3%) 38(63.3%) 42(70.0%) 864 ± 1158 922 ± 1228
Pol* 133 133 88(66.2%) 95(71.4%) 52(86.7%) 58(96.7%) 2598 ± 3069 3828 ± 4090
Env-gp120* 68 68 28(41.2%) 39(57.4%) 32(53.3%) 38(63.3%) 690 ± 1445 1034 ± 2062
Env-gp41* 46 46 17(37.0%) 31(67.4%) 29(48.3%) 45(75.0%) 649 ± 1377 943 ± 1389
Env* 114 114 45(39.5%) 70(61.4%) 46(76.7%) 52(86.7%) 1339 ± 2040 1976 ± 2624
Nef 27 27 26(96.3%) 24(88.9%) 52(86.7%) 51(85.0%) 2727 ± 4305 2812 ± 4217
Rev 15 14 10(66.7%) 9(64.3%) 18(30.0%) 28(46.7%) 552 ± 1421 590 ± 1105
Tat 13 13 7(53.8%) 6(46.2%) 10(16.7%) 9(15.0%) 283 ± 1103 132 ± 496
Vpu*# 9 9 8(88.9%) 3(33.3%) 9(15.0%) 3(5.0%) 144 ± 535 24 ± 115
Vpr 11 11 10(90.9%) 11(100%) 27(45.0%) 27(45.0%) 532 ± 1070 522 ± 988
Vif 24 24 13(54.2%) 19(79.2%) 20(33.3%) 37(61.7%) 576 ± 1627 762 ± 1483
Total * 413 412 263(63.7%) 296(71.8%) 60(100%) 60(100%) 13283 ± 
14223
15242 ± 
14353
1. * denotes a significant difference in responses targeting clade B and C OLPs (p value < 0.05, paired t test).
2. # denotes that the CTL responses to clade B OLPs targeting protease and Vpu are significantly stronger and broader than to clade C OLPsRetrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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The overall CTL responses in the study population Figure 1
The overall CTL responses in the study population. (A) 3-D figures depicting individual CTL responses showing similar 
clustering patterns targeting clade B and Clade C peptide sets. The CD4 counts of each subject are dotted in the left of the fig-
ures. (B) The average magnitudes induced by individual peptides covering the clades B and C proteome. (C) The recognition 
frequency of individual peptides by the study population. Inserted clade B fragments in the CRF07_BC genome are indicated as 
red bars adjacent to the X-axis. Significant differences were observed when comparing the average magnitude (B) and percent 
of responders (C) for different peptide sets.Retrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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detected are the corresponding clades B and C OLPs. Table
2 shows the pairs of immunodominant OLPs with differ-
ent percentages of responders targeting clade B or C pep-
tides. Notably, 26.7% of the subjects recognized the clade
C OLP designated as Pol-70(located in RT protein), how-
ever with only one amino acid substitution (G359T) it is
no longer detectable in the study subjects. It is also nota-
ble that there are 10 and 3 dominant epitopes identified
in RT and RNase respectively when tested by clade C pep-
tides, while only 3 and 0 identified by clade B peptides.
There are no immunodominant epitopes found in Pol-PR,
Tat and Vpu. The immunodominant regions are widely
distributed throughout the entire genome, with Gag, Pol
and Nef being the most frequently targeted. Compared to
the dominant epitopes scattered within the Gag protein,
those in Nef are clustered in the central region of the pro-
tein. The subdominant epitopes, targeted by more than
10% but less than 15% of the subjects, are mostly located
in p24, Nef, integrase, Vpr and Vif.
High cross-recognition of HIV-1 specific CTL responses
was observed in this study. When looking at the CTL rec-
ognition frequency at the single peptide level, along with
the distribution of immunodominant OLPs, the profile of
cross-recognition between clade B and C peptides can
clearly be seen (Figure 2). To further assess the cross-rec-
ognition of CTL responses to clades B and C peptides, the
two peptide sets were classified into the following catego-
ries, (i) both B and C peptides not recognized, (ii) both B
and C peptides recognized by at least one subject, (iii)
only C peptides recognized by at least one subject and (iv)
only B peptides recognized by at least one subject. The
results are represented with a Venn diagram (Figure 3) and
about 22% of the corresponding OLPs (92/413) derived
from both the clades B and C proteome are not targeted
by CTL. Of the remaining OLPs, more than 68% (219/
321) can be cross-recognized. We also analyzed the cross-
recognition by looking at the total CTL responses detected
by clades B and C peptide sets. There are 1352 responses
observed when applying clade B OLPs, and 1574
responses to clade C OLPs. Of the responses directed to
clade C OLPs, 61.75% (972/1574) can be observed when
tested with corresponding clade B OLPs.
Correlation of CTL responses with immune control of HIV-
1 infection
Firstly, we examined the correlation of CTL responses with
CD4 cell counts and viral loads and found that there are
no significant correlations between the overall breadth of
responses and the CD4 cell count or plasma viral load.
However, a weak negative correlation between the total
magnitude and the CD4 cell count was observed (R = -
0.260, p = 0.0442 for clade B OLP set; R = -0.283, p =
0.0285 for clade C OLP set, Pearson Correlation test).
Table 2: Sequence comparison of clade B and clade C immunodominant OLPs with different frequency of CTL Responses induced in 
the study population
OLP 
Numbering
Peptide Sequences Percent of Responders Average 
Magnitude of 
Responders
Clade B Clade C Location Clade B Clade C Clade B Clade C p-value
GAG-46 TILKALGPAATLEEMMTA TILRALGPGASLEEMMTA Gag (332 – 349) 23.33% 11.67% 553 334 0.022
POL-126 TKIQNFRVYYRDSRDPLW IKIQNFRVYYRDSRDPIW Pol (933 – 950) 16.67% 10.00% 535 358 0.027
VPR-4 ELKREAVRHFPRPWLHGL ELKQEAVRHFPRPWLHGL Vpr (25 – 42) 20.00% 15.00% 405 400 0.039
ENV-8 LFCASDAKAYDTEVHNVW LFCASDAKAYEKEVHNVW gp160 (52 – 69) 18.33% 8.33% 525 540 N.S.
VIF-15 LIHLYYFDCFSESAIRNAL I H MHYFDCFADSAIRKA Vif (106 – 123) 18.33% 6.67% 241 773 N.S.
GAG-03 EKIRLRPGGKKKYRLKHL EKIRLRPGGKKHYMLKHL Gag (17 – 34) 8.33% 20.00% 128 517 0.039
GAG-04 GKKKYRLKHLVWASREL GKKHYMLKHLVWASREL Gag (25 – 41) 11.67% 38.33% 911 670 0.023
GAG-51 TNSATIMMQRGNFRNQRK NSAILMQRSNFKGSKR Gag (371 – 388) 5.00% 16.67% 87 520 0.016
REV-03 RTVRLIKLLYQSNPL RAVRIIKILYQSNPY Rev (14 – 28) 11.67% 21.67% 197 754 0.013
POL-43 QGWKGSPAIFQCSMTKIL QGWKGSPAIFQSSMTKIL Pol (306 – 323) 10.00% 26.67% 268 672 0.000
POL-44 IFQCSMTKILEPFRK IFQSSMTKILEPFRA Pol (314 – 328) 6.67% 21.67% 163 371 0.010
POL-61 TKALTEVVPLTEEAELEL AKALTDIVPLTEEAELEL Pol (441 – 458) 6.67% 18.33% 460 723 0.020
POL-70 MRGAHTNDVKQLTEAVQK MRTAHTNDVKQLTEAVQK Pol (512 – 529) 0.00% 26.67% 0 441 0.002
POL-72 QKIATESIVIWGKTPKFK QKIAMESIVIWGKTPKFR Pol (528 – 545) 5.00% 21.67% 420 495 0.008
POL-81 DGAANRETKLGKAGYV DGAANRETKIGKAGYV Pol (598 – 613) 5.00% 20.00% 253 448 0.012
POL-82 ETKLGKAGYVTNKGRQKV ETKIGKAGYVTDRGRQKI Pol (604 – 621) 3.33% 16.67% 350 236 0.078
POL-85 QKTELQAIHLALQDSGL QKTELQAIYLALQDSGS Pol (630 – 646) 0.00% 20.00% 0 563 0.001
POL-109 PAETGQETAYFLLKLAGR PAETGQETAYFILKLAGR Pol (805 – 822) 13.33% 18.33% 264 352 N.S.
ENV-29 KVSFEPIPIHYCAPAGFA KVTFDPIPIHYCAPAGYA gp160 (207 – 224) 3.33% 18.33% 1120 1040 0.015
ENV-113 YRAILHIPTRIRQGLERA CRAIRNIPRRIRQGFEAA gp160 (837 – 854) 5.00% 28.33% 110 489 0.000
VIF-3 RIRTWKSLVKHHMYISKK KIRTWNSLVKHHMYVSRR Vif (17 – 34) 0.00% 16.67% 0 354 0.007
P values were for comparison of paired t-test and p = 0.05 is considered as statistic significance level.
The peptide location were indicated in the table in the reference of HIV-1 strain Hxb2.Retrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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When looking at specific HIV-1 proteins, we found that an
increased breadth of CTL responses targeting Gag (espe-
cially p24 and p15) resulted in decreased plasma viral
load, while for Nef and Vpu, increased breadth or magni-
tude of CTL responses corresponded to increased plasma
viral load. However, these correlates between the breadth
of CTL responses to specific proteins and the plasma viral
load can only be observed in consensus clade C peptide
sets, with the exception of p15. We then classified the sub-
jects into three groups based on their CD4 cell counts and
compared the breadth and magnitude of CTL responses.
The results show stronger and broader CTL responses in
subjects with CD4 cell counts ranging 200–400/mm3 than
those with less than 200/mm3 or more than 400/mm3. By
One Way Analysis of Variance (ANOVA), we find that
there are significant differences between the three groups
in CTL responses targeting clade B Gag (magnitude p =
0.046, breadth p = 0.006), clade B p17 (magnitude p =
0.020, breadth p = 0.027), and clade B p24 (breadth p =
0.022); clade C total breadth (p = 0.032), clade C gag
(breadth p = 0.022), clade C gag-p24 (breadth p = 0.009),
clade C Nef (breadth p = 0.045, magnitude p = 0.023),
and clade C gp41 (magnitude p = 0.024). However, by
pair wise multiple comparison, the differences with statis-
tical significance are only observed in the breadth of clade
B gag (200–400 vs. >400, unadjusted p = 0.00285; <200
vs. 200–400, unadjusted p = 0.0226), clade B gag-p17
(200–400 vs. >400, p < 0.05), clade B gag-p24 (200–400
vs. >400, p < 0.05), clade C gag-p24 (200–400 vs. >400,
unadjusted p = 0.00573; <200 vs. 200–400, unadjusted p
= 0.0222), clade C Nef (200–400 vs. >400, p < 0.05), and
in magnitude of clade B Gag-p17 (200–400 vs. >400, p <
0.05), Clade C Nef (200–400 vs. >400, p < 0.05). Figure 4
shows the different magnitudes and breadths of CTL
responses targeting Gag protein when the subjects were
classified using their CD4 cell counts.
Discussion
Several studies have been performed to characterize the
immune responses of HIV-1 infected populations of Chi-
nese origin [26-29]. However, these studies have focused
on subjects infected with the clade B virus, which circu-
lates throughout central China in former plasma donors.
As shown in the two nationwide HIV-1 molecular epide-
miological surveys performed in China in 1998 and 2004,
the B'/C recombinant strains (particularly CRF07_BC) are
circulating in western China from south to north [18-22].
This is the first study to address the profile of cellular
immune responses in Chinese subjects infected with HIV-
1 CRF07_BC.
It was reported that Gag, Pol and Nef are among the most
frequently targeted proteins by CTL in subjects infected
with HIV-1, including clades B and C [9,10,12,13,29,30].
Such clustering pattern of CTL epitopes in HIV-1 proteins
has led to the postulate that the frequency of CTL recogni-
tion is inversely correlated with the variability of the viral
sequences[31,32]. We have seen the similar clustering pat-
tern of CTL responses targeting HIV-1 proteins in this
study population infected with HIV-1 CRF07_BC.
Namely, Gag, Pol and Nef are among the most frequently
targeted proteins, while Vpu and Tat are rarely targeted
The immunodominance and cross-reactivity analysis Figure 2
The immunodominance and cross-reactivity analysis. The location of immunodominant and subdominant epitopes in 
the HIV-1 proteome. Five classes of recognition frequency are represented in the figure, (i) recognition frequency more than 
15%, (ii) more than 10% but less than 15%, (iii) more than 5% but less than 10%, (iv) more than 0% but less than 5% and (v) not 
recognized in the study population. Inserted clade B fragments in the CRF07_BC genome are indicated as red bars adjacent to 
X-axis.Retrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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(Figure 1, Table 1). Also, we have observed that Vpr and
Vif are targeted intensively. However, Pol-PR may be
exceptional to the postulate of inverse correlation
between frequency of CTL recognition and variability of
the viral sequences, as we have not observed immunodo-
minant epitopes in this relatively conserved protein
(Table 1, Figure 2).
The identification of immunodominant regions is crucial
for vaccine development and evaluation as these are the
targeted HIV regions that will be included in promising
vaccines [15]. Immune escape from immunodominant
epitopes can result in a broader spectrum of CTL
responses and in a faster development to AIDS[1,33] and
the host's genetic background may drive the elimination
of subdominant yet effective epitopes from circulating
viral population[34]. In this study, we identified 89
immunodominant OLPs scattering the HIV-1 proteins
except for Pol-PR, Tat and Vpu (Figure 2). We also
observed that the subdominant epitopes were also distrib-
uted throughout the HIV-1 expressed genome. When
comparing the patterns of dominant and subdominant
epitopes detected by clades B or C peptides, Pol and Vif
are notable for their discrepancies. The factors contribut-
ing such differentially targeting of clades B and C OLPs by
CTL responses could be the cumulative effect of immune
escapes during the HIV-1 epidemic in this population or
the founder effects of viral linage[35]. Anyway, our data
suggest that when incorporated into a vaccine construct,
Gag and Nef can more easily induce cross-clade CTL
responses, while the CTL responses induced by Pol and Vif
are more clade-specific.
High cross-clade CTL responses have previously been
extensively explored, especially in populations infected
with clade B[14,29,36]. Cross-clade CD8 T-cell responses
to HIV-1 CRF07_BC circulating in China have been
recorded in a previous study by using recombinant vac-
cinia viruses containing HIV-1 genes as stimulus antigen
[37]. However, by studying cross-clade CTL responses on
the single peptide level, new insight can be achieved,
keeping in mind that the homologous peptides can detect
CTL responses better than recombinant vaccinia viruses
expressed antigen and heterogeneous peptides [38]. We
have demonstrated here that for the B'/C recombinant
HIV-1 infected subjects, high cross recognition of consen-
sus clades B and C peptides is also evident. However, we
noticed that the B'/C recombinant strains contained part
of the clade B sequences in Gag, Pol, Env, Nef and acces-
sory genes except for Vif [18,21]. The relatively stronger
and broader responses directed to clade C peptides com-
pared with clade B was consistent with the reports in other
studies, which show that homologous peptides are better
at detecting CTL responses [38] and different from the
observation in another study on a Chinese population
infected with HIV-1 Thai B [29]. In the study by Zhao S et
al, they observed no significant differences between the
CTL responses targeting clade B and C peptide sets[29].
This may indicate that the recombinant form of HIV-1
CRF07_BC displays subtle differences in inducing the
host's immune responses. From the recognition patterns
in the clades B and C proteome, we can find that Pol-PR
and Vpu tend to be targeted in the clade B sequence rather
than the clade C sequence. These data are in line with the
recombinant pattern of CRF07_BC, the genome of which
are inserted with fragments of clade B sequences in pol-pr
and vpu [18,21,22].
In the past decade, the correlation between CTL responses
and immune control of HIV-1 infection has been exten-
sively explored and controversial results have been
reported[5,8,13,28,39-42]. A recent study has demon-
strated that CTL responses to different HIV proteins have
discordant associations with plasma viral load, which
results in effective CTL responses without a demonstrable
Area-proportional Venn diagram of cross recognition Figure 3
Area-proportional Venn diagram of cross recogni-
tion. The expressed whole genome of HIV-1 clade B or 
clade C were digested as 413 overlapping peptides and the 
two sets of peptides were tested in ELISPOT assay for each 
subject enrolled in this study. Cross-recognition of CTL 
responses to clade B and Clade C peptides were assessed by 
the classification of (i) both B and C peptides not recognized, 
(ii) both B and C peptides recognized by at least one subject, 
(iii) only C peptides recognized by at least one subject and 
(iv) only B peptides recognized by at least one subject.Retrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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Subjects grouped with different CD4 cell counts mounted a different magnitude and breadth of CTL responses targeting Gag Figure 4
Subjects grouped with different CD4 cell counts mounted a different magnitude and breadth of CTL responses 
targeting Gag. For each portion of the HIV-1 proteins (Gag, p17, p24 or p15), the total magnitude or breadth of each individ-
ual is dotted and the median values are shown as a dash. Black dots are responses targeting consensus clade B peptides and 
blue dots for responses targeting clade C peptides. The filled dots designate the values from the group of CD4 cell counts less 
than 200/µl, the circles for individuals with CD4 cell counts ranging from 200–400/µl and the triangles for CD4 cell counts 
more than 400/µl. The p values were obtained using One Way Analysis of Variance (ANOVA) for multiple group comparison 
and Dunn's method or Holm-Sidak method for pair wise multiple comparison, when appropriate for data distribution.Retrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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biological impact in chronic HIV infection[7]. The associ-
ation between the breadth of Gag-specific CTL responses
and low viremia has been confirmed in several popula-
tion based studies [6-8]. Consistent with these studies
[7,8], we have observed no statistically significant correla-
tion between total magnitude or breadth of CTL responses
and plasma viral load or CD4 cell count in this study. But
the data demonstrate that the relatively broader CTL
responses targeting Gag (especially Gag-p24 and p15) cor-
relate with lower plasma viral loads, and broader CTL
responses targeting Nef and Vpu correlate with increased
viral loads. The rationale behind this finding is still to be
elucidated. However, there are two possibilities to explain
the discordance. The first possibility is that Nef and Vpu-
specific CD8+ T-cell responses are as effective as Gag-spe-
cific responses in controlling viral replication, but the CTL
responses are recruited sequentially to different viral anti-
gens and escaped by virus with mutations in CTL epitopes
[1,43]. An alternative explanation is that Nef and Vpu-spe-
cific CTL responses are inherently less effective than Gag-
specific responses, partly due to the deleterious effect of
the viral mutation in CTL targeted Gag protein[44]. In line
with this, while several vaccine approaches that focus pri-
marily or exclusively upon generation of a CTL responses
protected macaques from disease, previous evidence also
suggests that CTL-based vaccines no matter raised against
densely conserved coding regions of HIV-1 spaning open
reading frames such as Env, Tat and Rev simultaneously,
can apparently always create viral escapes which are not
necessarily confer a fitness cost[45]. Put these together,
final validation of vaccine concept of eliciting protective
CTL responses against invading HIV-1 will have to be
obtained from large-scale efficacy clinical trial with prom-
ising HIV vaccines containing different viral products. The
fact that the correlates can only be observed when tested
with consensus clade C peptides other than clade B pep-
tides indicates that the choice of test peptide may have an
impact on the demonstration of the correlation between
the CTL responses and the containment of viral load.
The further analysis by grouping the research subjects on
basis of CD4 cell count, show that subjects with CD4 cell
ranging 200–400/mm3 mounted stronger CTL responses
than those with less than 200/mm3 or more than 400/
mm3. The results suggest that the correlation between
HIV-specific CTL responses and viral load in HIV-1 infec-
tion is dependent on disease status, which have been
recorded in previous reports that weaker anti-HIV CD8+
T-cell effector activity were observed in HIV primary infec-
tion compared with asymptomatic subjects with chronic
infection [28,46]. The decline of the HIV-1 specific CTL
responses late in disease progession is also obvious and
can be explained by the progressive depletion of CD4
helper T cells, which result in the inability of the body to
mount broader and stronger CD8 CTL response targeting
viral proteins [47], or by selective depletion of virus spe-
cific CTL [48] and the impaired proliferative capability of
virus specific CD8 CTL[49], which lead to decreased effec-
tor activity of previously induced CTL responses.
Conclusion
Overall, this is the first study addressing the profile of
immune responses in Chinese subjects infected with HIV-
1 B'/C recombinants. We have found similar CTL
response patterns as previous reports [9,10,12,13,29].
However, by comparing CTL responses targeting the
clades B and C proteome in the same population, we find
significant differences in the total magnitude and breadth
conferred by Gag-p17, Pol, and Env. This indicates that
the rapidly overspread CRF07_BC may have subtle differ-
ences in inducing a host's immune responses when com-
pared with the HIV-1 Thai B viral strain circulating in
central China.
Methods
Study population
Sixty IDUs infected with HIV-1 CRF07_BC were recruited
from Urumuqi at Xinjiang Uyghur Autonomous Region,
which is located in northwestern China. The clinical and
demographic characteristics of these subjects were as fol-
lows: median age, 32 years (range, 23–47 years); median
HIV-1 RNA, 21,550 copies/ml plasma (range, 49–
650,000 copies/ml plasma); median CD4 cell count, 339
cells/mm3 (range, 16–940 cells/mm3). All individuals
were anti-retroviral therapy naive at the time of study and
infected with HIV-1 CRF07_BC. The study was approved
by the institutional review board of National Center for
AIDS/STD Control and Prevention (NCAIDS, China-
CDC) and was conducted in accordance with human
experimentation guidelines.
Synthetic HIV-1-peptides
Four-hundred and thirteen synthetic 15–20 amino acid
long peptides, overlapping by 10 amino acids and span-
ning the entire HIV-1 clade B or C consensus sequence
[50], were synthesized at the Massachusetts General Hos-
pital (MGH) Peptide Core Facility on an automated pep-
tide synthesizer using Fmoc technology. All peptides were
synthesized at the same time and using the same reagents.
Except for a few cases of insertion or residue deletions
between clades, corresponding peptides from the different
consensus sequences were always of the same length and
spanned identical regions.
Elispot assays
Elispot assays were carried out as described previously
[30]. Briefly, peripheral blood mononuclear cells (PBMC)
isolated by Ficoll-paque™ Plus (Amersham Biosciences)
density gradient centrifugation were plated in 96-well pol-
yvinylidene plates that had been precoated with 100 µl ofRetrovirology 2007, 4:62 http://www.retrovirology.com/content/4/1/62
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anti-human interferon-gamma monoclonal antibody (0.5
µg/ml, Mabtech, Stockholm, Sweden). PBMCs were
plated at a concentration of 100000 cells/well in a volume
of 100 µl of RPMI 1640 medium supplemented with fetal
calf serum (10%), Hepes buffer (10 mM), L-glutamine (2
mM) and penicillin-streptomycin (50 U/ml). Corre-
sponding clades B and C peptides were combined into
pools of four to six peptides and tested individually when
a peptide pool gave a positive response. The final concen-
tration of the peptides in each well was 10 µg/ml. Plates
were incubated overnight at 37°C, 5% CO2 and devel-
oped the next day as described elsewhere [30]. Wells con-
taining PBMC and medium with PMA/Ionomycin or
without any peptide were used as positive or negative con-
trols, respectively, and run in triplicate on each plate. To
calculate the number of specific T cell responses, the
number of spots in the negative control wells was sub-
tracted from the counted number of spots in each well.
Responses were considered positive if there were > 50
spot-forming cells (SFC)/1 × 106 PBMC after subtracting
background and at least three times the mean number of
SFC of the three control wells.
Intracellular Cytokine Assay
ICS for IFN-gamma was performed as previously
described [51]. 1 × 106 PBMC were incubated with peptide
pools of 2 µg/ml Env, Gag, Pol, Nef and VVVRT(Vif, Vpr,
Vpu, Rev and Tat) along with anti-CD28 and anti-CD49
antibodies (BD Pharmingen) at 37°C and 5% CO2 for 1
hour before the addition of brefeldin A (10 µg/ml;
Sigma). The cells were incubated for an additional 5 hours
at 37°C and 5% CO2 and then washed and stained with
anti-CD4-PE and anti-CD8-APC antibodies (BD Pharmin-
gen) at 4°C for 30 min. The cells were fixed with solution
A (Caltag), permeabilized with solution B (Caltag), and
then stained with fluorescein isothiocyanate-conjugated
anti-IFN-gamma antibody. Flow cytometric analysis was
performed on FACSCalibur with CellQuest Pro (Becton
Dickinson). The FCS data were analyzed with FlowJo soft-
ware.
Statistical analysis
Results are given as means +/- SD or medians with ranges.
Statistical analysis was performed with SigmaPlot version
10.0 (Systat Software, Inc.) and based on Student t tests, a
Wilcoxon rank sum test, or a multiparametric ANOVA
test, as appropriate; a P < 0.05 was considered significant.
Viral-load values below the limit of detection of 50 RNA
copies/ml were assigned a value of 49 for statistical analy-
ses.
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